Back to Acceleration Radar
ALKSAlkermes Plc
Health Care · Biotechnology: Pharmaceutical Preparations · Mid
$43.63−1.24%
As of 23 Oct 2026Mkt cap $8.0B
Stage 13
WATCH
Fundamentals
41.5/75
Technical
7.6/15
Independent
49.1/90
GCAE viewbusiness is credible but technical recovery is not yet actionable
Price
- 1M
- +7.0%
- 3M
- −17.3%
- 6M
- +31.0%
- 1Y
- +40.3%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 114.8xHist median 15.4x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 15.7%
- Operating margin
- 24.9%
- FCF margin
- 32.5%
- Current ratio
- 3.5x
Growth
- Revenue growth
- −5.2%Latest FY YoY
- Revenue CAGR
- +5.9%
- EPS CAGR
- −17.5%
- FCF CAGR
- +59.8%
Capital
- Share-count trend
- −0.3%3Y annualised
- Net cash
- $389M-0.7x OCF
Annual trend
- CAGR 2021–2025
- +5.9%
- Latest · 2025
- $1B
- YoY
- −5.2%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
business is credible but technical recovery is not yet actionable
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-03
More details & evidence
Production decision
- Stage 13
- WATCH
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded